This morning Abbott (NYSE: ABT) issued a press release which stated;
“Abbott (ABT) today announced that the FreeStyle® Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). Coverage includes all Medicare patients with diabetes who use insulin and who meet the eligibility criteria.”
Naturally in response Dexcom (NASDAQ: DXCM) shares are falling, more like getting hammered. In early trading shares are down almost 10%.
To be honest Diabetic Investor . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.